Failure patterns and clinical implications in early stage nasal natural killer/T-cell lymphoma treated with primary radiotherapy

Cancer

Volumn 117, Issue 22, 2011, Pages 5203-5211

  Li, Ye Xiong ^a   Liu, Qing Feng ^a   Wang, Wei Hu ^a   Jin, Jing ^a   Song, Yong Wen ^a   Wang, Shu Lian ^a   Liu, Yue Ping ^a   Liu, Xin Fan ^a   Zhou, Li Qiang ^a   Yu, Zi Hao ^a  

^a CANCER HOSPITAL   (China)

Author keywords

chemotherapy; failure pattern; NK T cell lymphoma; prognosis; radiotherapy

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; METHOTREXATE; PREDNISONE; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER GROWTH; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM; CERVICAL LYMPH NODE; CHILD; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NK T CELL LYMPHOMA; NONHODGKIN LYMPHOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PARANASAL SINUS; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RISK FACTOR; SCHOOL CHILD; THORAX RADIOGRAPHY; TREATMENT FAILURE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPHOMA, EXTRANODAL NK-T-CELL; MALE; MIDDLE AGED; NOSE NEOPLASMS; RISK FACTORS; SURVIVAL RATE; TREATMENT FAILURE;

EID: 80052036837     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26167     Document Type: Article

References (44)

1. Aviles A, Diaz NR, Neri N, et al. Angiocentric nasal T/natural killer cell lymphoma: a single center study of prognostic factors in 108 patients. Clin Lab Haematol. 2000; 22: 215-220.
2. Au WY, Weisenburger DD, Intragumtornchai T, et al. Clinical differences between nasal and extranasal NK/T-cell lymphoma: a study of 136 cases from the International Peripheral T-cell Lymphoma Project. Blood. 2009; 113: 3931-3937.
3. Li YX, Yao B, Jin J, et al. Radiotherapy as primary treatment for stage IE and IIE nasal natural killer/T-cell lymphoma. J Clin Oncol. 2006; 24: 181-189. (Pubitemid 46630511)
4. Kim TM, Lee SY, Jeon YK, et al. Clinical heterogeneity of extranodal NK/T-cell lymphoma, nasal type: a national survey of the Korean Cancer Study Group. Ann Oncol. 2008; 19: 1477-1484.
5. Bossard C, Belhadj K, Reyes F, et al. Expression of the granzyme B inhibitor PI9 predicts outcome in nasal NK/T-cell lymphoma: results of a Western series of 48 patients treated with first-line polychemotherapy within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials. Blood. 2007; 109: 2183-2189. (Pubitemid 46348221)
6. Lee J, Suh C, Park YH, et al. Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J Clin Oncol. 2006; 24: 612-618. (Pubitemid 46630424)
7. Li YX, Liu QF, Fang H, et al. Variable clinical presentations of nasal and Waldeyer ring natural killer/T-cell lymphoma. Clin Cancer Res. 2009; 15: 2905-2912.
8. Lee J, Park YH, Kim WS, et al. Extranodal nasal type NK/T-cell lymphoma: elucidating clinical prognostic factors for risk-based stratification of therapy. Eur J Cancer. 2005; 41: 1402-1408. (Pubitemid 40826463)
9. Barrionuevo C, Zaharia M, Martinez MT, et al. Extranodal NK/T-cell lymphoma, nasal type: study of clinicopathologic and prognosis factors in a series of 78 cases from Peru. Appl Immunohistochem Mol Morphol. 2007; 15: 38-44. (Pubitemid 46673314)
10. Huang MJ, Jiang Y, Liu WP, et al. Early or up-front radiotherapy improved survival of localized extranodal NK/T-cell lymphoma, nasal-type in the upper aerodigestive tract. Int J Radiat Oncol Biol Phys. 2008; 70: 166-174. (Pubitemid 350251036)
11. Yang Y, Zhang YJ, Lin XB, et al. Role of radiotherapy in the treatment of patients with early stage extranodal nasal-type NK/T-cell lymphoma and analysis of prognostic factors. Chin J Radiat Oncol. 2009; 18: 285-289.
12. Nie DH, Xie FY, Li JS, et al. Treatment modality and prognostic analysis of early stage nasal NK/T-cell lymphoma. Chin J Radiat Oncol. 2010; 19: 315-319.
13. Kim K, Chie EK, Kim CW, et al. Treatment outcome of angiocentric T-cell and NK/T-cell lymphoma, nasal type: radiotherapy versus chemoradiotherapy. Jpn J Clin Oncol. 2005; 35: 1-5. (Pubitemid 40450547)
14. Aikemu W, Wang RZ, Li PD,. A clinical study of 57 patients with extranodal natural killer/T-cell lymphoma, nasal-type. J Xinjiang Med Univ. 2008; 31: 1507-1509.
15. Ma HH, Qian LT, Pan HF, et al. Treatment outcome of radiotherapy alone versus radiochemotherapy in early stage nasal natural killer/T-cell lymphoma. Med Oncol. 2010; 27: 798-806.
16. Wang ZY, Li YX, Wang WH, et al. Primary radiotherapy showed favorable outcome in treating extranodal nasal-type NK/T-cell lymphoma in children and adolescents. Blood. 2009; 114: 4771-4776.
17. You JY, Chi KH, Yang MH, et al. Radiation therapy versus chemotherapy as initial treatment for localized nasal natural killer (NK)/T-cell lymphoma: a single institute survey in Taiwan. Ann Oncol. 2004; 15: 618-625.
18. Chim CS, Ma SY, Au WY, et al. Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index. Blood. 2004; 103: 216-221.
19. Li CC, Tien HF, Tang JL, et al. Treatment outcome and pattern of failure in 77 patients with sinonasal natural killer/T-cell or T-cell lymphoma. Cancer. 2004; 100: 366-375.
20. Kim GE, Lee SW, Chang SK, et al. Combined chemotherapy and radiation versus radiation alone in the management of localized angiocentric lymphoma of the head and neck. Radiother Oncol. 2001; 61: 261-269. (Pubitemid 33127230)
21. Cheung MM, Chan JK, Lau WH, et al. Early stage nasal NK/T-cell lymphoma: clinical outcome, prognostic factors, and the effect of treatment modality. Int J Radiat Oncol Biol Phys. 2002; 54: 182-190.
22. Isobe K, Uno T, Tamaru JI, et al. Extranodal natural killer/T-cell lymphoma, nasal type. Cancer. 2006; 106: 609-615.
23. Koom WS, Chung EJ, Yang WI, et al. Angiocentric T-cell and NK/T-cell lymphomas: radiotherapeutic viewpoints. Int J Radiat Oncol Biol Phys. 2004; 59: 1127-1137. (Pubitemid 38834307)
24. Chan JKC, Quintanilla-Martinez L, Ferry JA, et al. Extranodal NK/T-cell lymphoma, nasal type. In:, Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2008: 285-288.
25. Shipp MA, Harrington DP, Anderson JR, et al. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993; 329: 987-994. (Pubitemid 23307906)
26. Li YX, Fang H, Liu QF, et al. Clinical features and treatment outcome of nasal-type NK/T-cell lymphoma of Waldeyer ring. Blood. 2008; 112: 3057-3064.
27. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999; 17: 1244-1253. (Pubitemid 29162950)
28. Ma X, Guo Y, Pang Z, et al. A randomized phase II study of CEOP with or without semustine as induction chemotherapy in patients with stage I(E)/II(E) extranodal NK/T-cell lymphoma, nasal type in the upper aerodigestive tract. Radiother Oncol. 2009; 93: 492-497.
29. Smalley SR, Cupps RE, Anderson J, et al. Polymorphic reticulosis limited to the upper aerodigestive tract: natural history and radiotherapeutic considerations. Int J Radiat Oncol Biol Phys. 1988; 15: 599-605.
30. Sakata K, Fuwa N, Kodaira T, et al. Analyses of dose-response in radiotherapy for patients with mature T/NK-cell lymphomas according to the WHO classification. Radiother Oncol. 2006; 79: 179-184. (Pubitemid 43867811)
31. Ishida F, Nishina S, Asano N, et al. Late relapse of extranodal natural killer/T cell lymphoma, nasal type, after more than ten years. Leuk Lymph. 2010; 51: 171-173.
32. Schrader C, Janssen D, Kneba M, et al. A 38-year history of natural-killer-cell lymphoma. N Engl J Med. 2004; 350: 418-419.
33. Wang B, Lu JJ, Ma X, et al. Combined chemotherapy and external beam radiation for stage IE and IIE natural killer T-cell lymphoma of nasal cavity. Leuk Lymph. 2007; 48: 396-402. (Pubitemid 46994891)
34. Kim SJ, Kim BS, Choi CW, et al. Treatment outcome of front-line systemic chemotherapy for localized extranodal NK/T cell lymphoma in nasal and upper aerodigestive tract. Leuk Lymph. 2006; 47: 1265-1273. (Pubitemid 44269633)
35. Kim TM, Heo DS,. Extranodal NK/T-cell lymphoma, nasal type: new staging system and treatment strategies. Cancer Sci. 2009; 100: 2242-2248.
36. Kako S, Izutsu K, Ota Y, et al. FDG-PET in T-cell and NK-cell neoplasms. Ann Oncol. 2007; 18: 1685-1690. (Pubitemid 47506256)
37. Huang WT, Chang KC, Huang GC, et al. Bone marrow that is positive for Epstein-Barr virus encoded RNA-1 by in situ hybridization is related with a poor prognosis in patients with extranodal natural killer/T-cell lymphoma, nasal type. Haematologica. 2005; 90: 1063-1069.
38. Yamaguchi M, Tobinai K, Oguchi M, et al. Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211. J Clin Oncol. 2009; 27: 5594-5600.
39. Kim SJ, Kim K, Kim BS, et al. Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-cell lymphoma: consortium for improving survival of lymphoma study. J Clin Oncol. 2009; 27: 6027-6032.
40. Lee KW, Yun T, Kim DW, et al. First-line ifosfamide, methotrexate, etoposide and prednisolone chemotherapy radiotherapy is active in stage I/II extranodal NK/T-cell lymphoma. Leuk Lymph. 2006; 47: 1274-1282. (Pubitemid 44269634)
41. Yong WB, Zheng W, Zhu J, et al. L-Asparaginase in the treatment of refractory and relapsed extranodal NK/T-cell lymphoma, nasal type. Ann Hematol. 2009; 88: 647-652.
42. Bernstein SH, Unger JM, LeBlanc M, et al. Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: a 20-year follow-up analysis of SWOG 8516â The Southwest Oncology Group. J Clin Oncol. 2008; 27: 114-119.
43. Villa D, Connors JM, Shenkier TN, et al. Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy. Ann Oncol. 2010; 21: 1046-1052.
44. Kim SJ, Oh SY, Hong JY, et al. When do we need central nervous system prophylaxis in patients with extranodal NK/T-cell lymphoma, nasal type? Ann Oncol. 2010; 21: 1058-1063.